Matthew McMenemy, MD
Ophthalmology · Sugar Land, TXNPI 1700842267
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $111,235 of the $150,061 with a category attached, or 74.1%. 35 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 51.4% of the total. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 633 payments — averaging $237.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$77K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$32K
- Novartis$18K
- Kala Pharmaceuticals, Inc.$5K
- Regeneron$2K
- Alcon$2K
- plus $13K from 29 others
Across 30 payments — averaging $480.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$14K
What the payments were for
- Consulting fees$10,8257%
- Speaking & faculty fees$111,23574%
- Travel & lodging$9,4056%
- Food & beverage$17,82612%
- Other$7701%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYZULTA$105,647
- TRAVATAN Z$17,294
- EYSUVIS$3,800
- EYLEA$2,450
- Rhopressa$1,264
- Rocklatan$1,264
- INVELTYS$1,119
- Tobradex ST$1,000
- LUMERA 300$770
- XIIDRA$351
- OMNI(R) SURGICAL SYSTEM (US)$288
- LOTEMAX SM$265
- TRYPTYR$252
- MIEBO$249
- VUITY$247
- VEVYE$245
- LUMIGAN$245
- TEPEZZA$244
- XDEMVY$240
- DURYSTA$238
How this compares
$150,061 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 54 | $81,028 |
| VyzultaLatanoprostene Bunod | 148 | $73,047 |
| LumiganBimatoprost | 132 | $68,767 |
| RestasisCyclosporine | 55 | $63,954 |
| XdemvyLotilaner | 27 | $50,518 |
| Lotemax SmLoteprednol Etabonate | 170 | $41,807 |
| ProlensaBromfenac Sodium | 116 | $39,668 |
| Latanoprost | 2,676 | $37,420 |
| BesivanceBesifloxacin Hcl | 166 | $36,253 |
| RocklatanNetarsudil Mesylat/Latanoprost | 44 | $36,047 |
| CombiganBrimonidine Tartrate/Timolol | 78 | $35,088 |
| RhopressaNetarsudil Mesylate | 55 | $33,885 |
| Travoprost | 161 | $30,965 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 66 | $25,707 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 88 | $22,352 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $2,273 | $167,808265 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $77,196 | $154,075202 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa, Besivance, Loteprednol Etabonate | $32,110 | $125,006515 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $1,178 | $69,93299 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $523 | $50,51827 claims |
| AlconSimbrinza | $2,396 | $25,70766 claims |
| Harrow Eye, LLCVevye | $550 | $20,27719 claims |
| NovartisTravatan Z | $17,825 | $9,09611 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $385 | $9,09115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Sugar Land
- Michael SingerSan Antonio$1.8M
- Oluwatosin SmithDallas$1.5M
- Charles WykoffBellaire$1.5M
- John MichelettiHouston$916K
- Davinder GroverDallas$705K
- Christina WengHouston$676K
- Peter ChangHouston$656K
- Zaina Al-MohtasebHouston$636K
- Ashkan AbbeyDallas$559K
- Stephen SladeHouston$530K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.